This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

fact-checked

peer-reviewed publication

reputable news agency

proofread

Model predicts need for bone marrow sampling in monoclonal gammopathy of undetermined significance

Model predicts need for bone marrow sampling in monoclonal gammopathy of undetermined significance

A recently developed multivariable model can accurately predict smoldering multiple myeloma (SMM) or worse in persons with presumed monoclonal gammopathy of undetermined significance (MGUS), according to a study published online April 2 in the Annals of Internal Medicine.

Elias Eythorsson, M.D., Ph.D., from the University of Iceland in Reykjavik, and colleagues developed a multivariable prediction model that predicts the probability that a person with presumed MGUS has 10% or greater bone marrow plasma cells (SMM or worse by bone marrow criteria) to inform the decision to obtain a bone marrow sample. In addition, performance of the prediction model was compared to performance of the Mayo Clinic risk stratification model. The study included 1,043 adults with immunoglobulin G (IgG), IgA, light-chain, and biclonal MGUS and an interpretable bone marrow sample.

The researchers found that the C-statistic was 0.85 for SMM or worse, and calibration was excellent. Sensitivity and specificity were 86 and 67%, respectively, at a threshold of 10% predicted risk for SMM or worse; positive and negative predictive values were 32 and 96%, respectively. Across a range of plausible low-risk thresholds, the net benefit for the decision to refer for sampling was 0.13 to 0.30 higher compared with the Mayo Clinic model.

"Persons with predicted risks below the relevant low-risk threshold could safely defer bone marrow and be managed by as presumed MGUS," the authors write.

More information: Elias Eythorsson et al, Development of a Multivariable Model to Predict the Need for Bone Marrow Sampling in Persons With Monoclonal Gammopathy of Undetermined Significance, Annals of Internal Medicine (2024). DOI: 10.7326/M23-2540

Journal information: Annals of Internal Medicine

© 2024 HealthDay. All rights reserved.

Citation: Model predicts need for bone marrow sampling in monoclonal gammopathy of undetermined significance (2024, April 2) retrieved 24 June 2024 from https://medicalxpress.com/news/2024-04-bone-marrow-sampling-monoclonal-gammopathy.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Bone marrow adipocytes provide early sign of progression from MGUS to multiple myeloma

1 shares

Feedback to editors